Clinical Trials Logo

Seasickness clinical trials

View clinical trials related to Seasickness.

Filter by:
  • None
  • Page 1

NCT ID: NCT05640258 Completed - Seasickness Clinical Trials

Seasickness Susceptability and Vestibular Time Constant

Start date: September 18, 2017
Phase: N/A
Study type: Interventional

Participants were selected from the military navy crewmembers prior to commencing of active sailing. A vestibular time constant was calculated based on velocity step testing on a rotatory chair at baseline, 3 months and 6 month following active sailing duty. A seasickness questionnaire (WIKER) was completed during follow-up visits. study participants were divided to three groups based on WIKER score - susceptible , non-susceptible and habituating. Vestibular time constant was compared between study groups.

NCT ID: NCT05004818 Completed - Motion Sickness Clinical Trials

Galvanic Vestibular Stimulation as a Novel Treatment for Seasickness

Start date: August 1, 2016
Phase: N/A
Study type: Interventional

subjects with severe seasickness, who failed to habituate to sea conditions after at least six month of active sailing, were enrolled to the single-blind randomized control study. The intervention group was treated with rotatory chair stimulation at sinusoidal harmonic acceleration protocol coupled with galvanic vestibular stimulation to the mastoid processes. This unique procedure was hypothesized to promote habituation to seasickness. The control group underwent a sham procedure. All study participants filled out seasickness questionnaires at set time points following the intervention and underwent repeated step testing to determine their vestibular time constant. The number of anti-motion sickness clinic visits and scopolamine prescriptions was also recorded in the three months period following the intervention.

NCT ID: NCT04482985 Not yet recruiting - Seasickness Clinical Trials

Meclizine Plasma Levels in Responders and Non-responders

Start date: September 1, 2020
Phase: Phase 4
Study type: Interventional

Motion sickness is a debilitating condition that can effect many crew members. Meclizine has long been known as an effective anti motion sickness drug. The response to the drug is variable - some are responders, while others are resistant to the drug. The aim of the present study is to examine whether there is a correlation between meclizine plasma levels and clinical response.